Summary of the technology
The proposed invention is a novel target, Phophoinositides, for the treatment of Parkinson’s disease, based on a new mechanism, associating increased levels of membrane phospholipids with alpha-Syn-related toxicity.
Key words: Parkinson’s disease; alpha-Synuclein; Phosphatidylinositol; phosphatidylinositol 4,5-bisphosphate (PI4,5P2); striosomes; axonal injury; axonal branching
Project ID : 6-2018-4627
Description of the technology
Parkinson’s disease, PD, Central Nervous System, CNS
Current development stage
TRL3 - Hypothesis testing and intial POC demonstrated in limited number of in-vitro models;
- Parkinson disease (PD) is a long-term, progressive neurodegenerative disorder of thecentral nervous system, which results in motor and non-motor dysfunction. The disease is primarily related to loss of dopaminergic function. The market of Parkinson’s diseasetreatments is driven by the growth in aging population and the associated increase in the prevalence of PD, however , there is currently nocure for Parkinson's disease, with treatment mostly associated with Dopamine replacement therapy, directed at improving symptoms.
- The Researcher identified a possibly new target , with proposed mechanism of action associated with α-Syn toxicity in PD. Initial pre-clinical results suggest a novel therapeutic approach , using specific inhibitors to stop progression of Parkinson’s disease.
VP Business Development Healthcare
HUJI, School of Medicine - IMRIC
Biochemistry and Molecular Biology
About Yissum - Research Development Company of the Hebrew University
Technology Transfer Office from IsraelYissum - Research Development Company of the Hebrew University
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.